Transforming growth factor-beta: a target for cancer therapy (Q37633528)

21 August 2017

1 reference

title

Transforming growth factor-beta: a target for cancer therapy (English)

1 reference

21 August 2017

Ronan J Kelly

1 reference

21 August 2017

John C Morris

series ordinal

1 reference

21 August 2017

publication date

1 March 2010

1 reference

Journal of Immunotoxicology

21 August 2017

published in

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

15-26

1 reference

Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Novel mechanisms for antisense-mediated regulation of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Tumor-stroma interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGFBR1*6A may contribute to hereditary colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Role of transforming growth factor beta in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Myc represses transcription through recruitment of DNA methyltransferase corepressor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Molecular mechanisms of action of antisense drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGF-beta signaling in tumor suppression and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Role of transforming growth factor-beta in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Targeting the TGF beta signaling network in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Role of transforming growth factor Beta in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Specificity and versatility in tgf-beta signaling through Smads

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

The organ microenvironment and cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGF-β signalling from cell membrane to nucleus through SMAD proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

The basics of epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGF-beta superfamily signaling is essential for tooth and hair morphogenesis and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/activin receptor-like kinase-5, on prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Ubiquitin-dependent degradation of TGF-beta-activated smad2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Repression of Smad4 transcriptional activity by SUMO modification

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Betaglycan presents ligand to the TGF beta signaling receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Immature, but not inactive: the tolerogenic function of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGF-beta signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

How cells read TGF-beta signals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

The logic of TGFbeta signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Smad transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Invasion and metastasis of a mammary tumor involves TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Non-Smad TGF-beta signals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Metastasis is driven by sequential elevation of H-ras and Smad2 levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Somatic acquisition and signaling of TGFBR1*6A in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Escaping from the TGFbeta anti-proliferative control

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Macrophage-derived angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Endoglin in angiogenesis and vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Epithelial-mesenchymal transitions in development and pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Epithelial cell plasticity in development and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Reversal of tumor-induced immunosuppression by TGF-beta inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15476910903389920

10.3109/15476910903389920

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference